No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 27,451 | 25,305 | 33,147 | 35,083 | 38,020 | 39,651 | 42,909 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 3,955 | 4,232 | 5,177 | 9,277 | 9,437 | 10,915 | 7,867 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1972 and headquartered in Hyderabad, India, Nava Limited operates as a diversified international enterprise with core activities spanning power generation, mining, ferro alloys manufacturing, and healthcare services. Its global reach extends to India, Zambia, Hong Kong, Japan, and Singapore, among other markets. In its power division, the company produces and sells electricity from various fuel sources, including coal, biomass, biogas, and bagasse. Its significant power assets in India include 150 MW and 114 MW plants in Paloncha, Telangana; a 150 MW facility in Kharagprasad, Odisha; and a 20 MW biomass plant in Dharmavaram, Andhra Pradesh. Internationally, it runs a 300 MW thermal power plant in Zambia, while also offering operation and maintenance expertise for power facilities. The mining segment is engaged in coal extraction at Maamba in Zambia's Southern province. Its ferro alloys business manufactures a variety of specialized metals, such as ferro chrome, silico manganese, ferro silicon, and other chromium alloys, which are crucial components in the automotive, railway, and construction industries, as well as in the production of stainless-steel consumer products. Nava's healthcare ventures include the management of The Iron Suites Medical Center in Singapore, specializing in the treatment of iron deficiency and the administration of intravenous iron. This division also oversees corporate healthcare programs, organizes medical conferences and public awareness campaigns, and is involved in licensing pharmaceutical products. Formerly known as Nava Bharat Ventures Limited, the company rebranded to Nava Limited in July 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1972 and headquartered in Hyderabad, India, Nava Limited operates as a diversified international enterprise with core activities spanning power generation, mining, ferro alloys manufacturing, and healthcare services. Its global reach extends to India, Zambia, Hong Kong, Japan, and Singapore, among other markets. In its power division, the company produces and sells electricity from various fuel sources, including coal, biomass, biogas, and bagasse. Its significant power assets in India include 150 MW and 114 MW plants in Paloncha, Telangana; a 150 MW facility in Kharagprasad, Odisha; and a 20 MW biomass plant in Dharmavaram, Andhra Pradesh. Internationally, it runs a 300 MW thermal power plant in Zambia, while also offering operation and maintenance expertise for power facilities. The mining segment is engaged in coal extraction at Maamba in Zambia's Southern province. Its ferro alloys business manufactures a variety of specialized metals, such as ferro chrome, silico manganese, ferro silicon, and other chromium alloys, which are crucial components in the automotive, railway, and construction industries, as well as in the production of stainless-steel consumer products. Nava's healthcare ventures include the management of The Iron Suites Medical Center in Singapore, specializing in the treatment of iron deficiency and the administration of intravenous iron. This division also oversees corporate healthcare programs, organizes medical conferences and public awareness campaigns, and is involved in licensing pharmaceutical products. Formerly known as Nava Bharat Ventures Limited, the company rebranded to Nava Limited in July 2022.
